CDK 4/6 Drug Interactions
Last Reviewed March 2025
Disclaimer: This content is provided for educational purposes only and is not a substitute for independent clinical judgment. Always consult official product monographs and prescribing information before making treatment decisions. Do not delay or disregard professional medical advice because of information on this site. Use of this resource does not establish a physician–patient relationship. See the full disclaimer for details.
Palbociclib Interactions
Acetylsalicylic acid
No clinically significant drug interactions identified.
Alendronate
No clinically significant drug interactions identified.
Allopurinol
No clinically significant drug interactions identified.
Alprazolam
Caution - increased level of alprazolam due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Amiodarone
Caution - increased level of amiodarone due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Amitriptyline
No clinically significant drug interactions identified.
Amlodipine
No clinically significant drug interactions identified.
Amoxi/clav
No clinically significant drug interactions identified.
Amoxicillin
No clinically significant drug interactions identified.
Amphetamine / Dextroamphetamine
No clinically significant drug interactions identified.
Apixaban
No clinically significant drug interactions identified.
Aripiprazole
No clinically significant drug interactions identified.
Atenolol
No clinically significant drug interactions identified.
Atomoxetine
No clinically significant drug interactions identified.
Atorvastatin
Caution - increased level of atorvastatin due to 3A4 inhibition. Monitor for signs of toxicity. If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Azithromycin
No clinically significant drug interactions identified.
Baclofen
No clinically significant drug interactions identified.
Bisoprolol
No clinically significant drug interactions identified.
Buprenorphine/ naloxone
Caution - increased level of buprenorphine/naloxone due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Bupropion
No clinically significant drug interactions identified.
Buspirone
No clinically significant drug interactions identified.
Calcium Carbonate
No clinically significant drug interactions identified.
Canagliflozin
No clinically significant drug interactions identified.
Candesartan
No clinically significant drug interactions identified.
Carbamazepine
Avoid combination - decreased level of palbociclib due to 3A4 induction. Choose an alternative agent.
Carvedilol
No clinically significant drug interactions identified.
Celecoxib
No clinically significant drug interactions identified.
Cephalexin
No clinically significant drug interactions identified.
Cetirizine
No clinically significant drug interactions identified.
Chlorthalidone
No clinically significant drug interactions identified.
Cholecalciferol
No clinically significant drug interactions identified.
Ciprofloxacin
No clinically significant drug interactions identified.
Citalopram
No clinically significant drug interactions identified.
Clarithromycin
Avoid combination - increased level of palbociclib due to 3A4 inhibition. Choose an alternative agent.
Clindamycin
No clinically significant drug interactions identified.
Clonazepam
No clinically significant drug interactions identified.
Clonidine
No clinically significant drug interactions identified.
Clopidogrel
No clinically significant drug interactions identified.
Codeine
Caution - increased level of codeine due to 3A4 inhibition. Monitor for signs of toxicity (sedation, confusion, dizziness). If initiating therapy, titrate slowly. If already established on therapy, may require dose reduction. Consider choosing an alternative agent.
Colchicine
No clinically significant drug interactions identified.
Cyclobenzaprine
No clinically significant drug interactions identified.
Dabigatran
No clinically significant drug interactions identified.
Dapagliflozin
No clinically significant drug interactions identified.
Desvenlafaxine
No clinically significant drug interactions identified.
Dexamethasone
No clinically significant drug interactions identified.
Dexlansoprazole
No clinically significant drug interactions identified.
Diazepam
No clinically significant drug interactions identified.
Diclofenac
No clinically significant drug interactions identified.
Digoxin
No clinically significant drug interactions identified.
Diltiazem
Caution - increased level of both agents due to 3A4 inhibition. Monitor for signs of toxicity. Consider choosing an alternative agent.
Dimenhydrinate
No clinically significant drug interactions identified.
Divalproex
No clinically significant drug interactions identified.
Docusate
No clinically significant drug interactions identified.
Domperidone
No clinically significant drug interactions identified.
Donepezil
No clinically significant drug interactions identified.
Doxazosin
No clinically significant drug interactions identified.
Doxycycline
No clinically significant drug interactions identified.
Doxylamine/ Pyridoxine
No clinically significant drug interactions identified.
Duloxetine
No clinically significant drug interactions identified.
Dutasteride
No clinically significant drug interactions identified.
Edoxaban
No clinically significant drug interactions identified.
Eletriptan
No clinically significant drug interactions identified.
Empagliflozin
No clinically significant drug interactions identified.
Enalapril
No clinically significant drug interactions identified.
Escitalopram
No clinically significant drug interactions identified.
Esomeprazole
No clinically significant drug interactions identified.
Ezetimibe
No clinically significant drug interactions identified.
Famotidine
No clinically significant drug interactions identified.
Fenofibrate
No clinically significant drug interactions identified.
Finasteride
No clinically significant drug interactions identified.
Fluconazole
Caution - increased level of palbociclib due to 3A4 inhibition. Use lowest dose and shortest duration as clinically indicated. Monitor for signs of palbociclib toxicity. Consider choosing an alternative agent.
Fluoxetine
No clinically significant drug interactions identified.
Folic Acid
No clinically significant drug interactions identified.
Fosfomycin
No clinically significant drug interactions identified.
Furosemide
No clinically significant drug interactions identified.
Gabapentin
No clinically significant drug interactions identified.
Galantamine
No clinically significant drug interactions identified.
Gliclazide
No clinically significant drug interactions identified.
Glyburide
No clinically significant drug interactions identified.
Guanfacine
No clinically significant drug interactions identified.
Hydralazine
No clinically significant drug interactions identified.
Hydrochlorothiazide
No clinically significant drug interactions identified.
Hydromorphone
No clinically significant drug interactions identified.
Hydroxychloroquine
No clinically significant drug interactions identified.
Hydroxyzine
No clinically significant drug interactions identified.
Ibuprofen
No clinically significant drug interactions identified.
Indapamide
No clinically significant drug interactions identified.
Indomethacin
No clinically significant drug interactions identified.
Irbesartan
No clinically significant drug interactions identified.
Isotretinoin
No clinically significant drug interactions identified.
Itraconazole
Avoid combination - increased level of palbociclib due to 3A4 inhibition. Choose an alternative agent.
Ketorolac
No clinically significant drug interactions identified.
Labetalol
No clinically significant drug interactions identified.
Lansoprazole
No clinically significant drug interactions identified.
Levetiracetam
No clinically significant drug interactions identified.
Levodopa/carbidopa
No clinically significant drug interactions identified.
Levofloxacin
No clinically significant drug interactions identified.
Levothyroxine
No clinically significant drug interactions identified.
Linagliptin
No clinically significant drug interactions identified.
Liraglutide
No clinically significant drug interactions identified.
